Robert Orlowski, MD
Enriched profileChair, Lymphoma/Myeloma (2025-present); Deputy Chair, Myeloma Translational Research, Division of Cancer Medicine; Professor, Lymphoma/Myeloma; Florence Maude Thomas Cancer Research Professor · The University of Texas MD Anderson Cancer Center
Robert Orlowski is Chair, Lymphoma/Myeloma (2025-present); Deputy Chair, Myeloma Translational Research, Division of Cancer Medicine; Professor, Lymphoma/Myeloma; Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,164 publications with 54,018 citations (h-index 102); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Robert Orlowski as a Highly Cited Researcher (Clinical Medicine, 2021-2023).
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Robert Orlowski, MD, is Chair, Lymphoma/Myeloma (2025-present) at The University of Texas MD Anderson Cancer Center. The public record shows 1,164 publications with 54,018 citations (h-index 102), centered on Multiple Myeloma, Leukemia (AML/ALL/CML/CLL), Breast Cancer. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 20 companies, 6 NIH-funded awards (2008–2026).
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Multiple Myeloma
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 20 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 43 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 14 Oct 2026
20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20255 payments
- PFIZER INC.Program year20253 payments
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
61.7%Thalidomide Analog61.7%Lenalidomide48%Revlimid38%Pomalyst14%Part D<11 patientsAnti-infectives
17.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor17.6%Valacyclovir100%Part D≥29 patientsSensory organs
10.2%Corticosteroid10.2%Dexamethasone100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
6 NIH research awards on record, funded 2008–2026 per NIH RePORTER. The latest:
- Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas
University of Tx Md Anderson Can Ctr
FY2026$483,912R01CA266612 - Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas
University of Tx Md Anderson Can Ctr
FY2025$483,912R01CA266612
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/cv/robert-orlowski-md-phd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/robert-orlowski-5b548915
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/Myeloma_Doc
Mentions by others
where others cite or feature them- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - X / Twitter
X (Twitter) account apparently belonging to Robert Z. Orlowski: @Myeloma_Doc
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- Editorial Board
Blood Cancer Discovery
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Editorial Board
Clinical Cancer Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Chair
SWOG Myeloma Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Member
NCI Myeloma Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine202120222023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →expertperspectives.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →expertperspectives.com ↗
Secondary affiliations
appointments beyond the home institution- Professor (Joint Appointment)
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncbrothers.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- mPatient Myeloma Radio interview with Dr. Robert Orlowski
MD, PhD, MD Anderson
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens